title: Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
abstract: Serotonin (5-HT) may play a regulatory role in platelet-vessel wall interaction. This can be reliably investigated by measuring bleeding time. Ketanserin is a recently developed selective 5-HT2 receptor antagonist, reportedly effective against both platelet and vascular 5-HT activation. Ketanserin (5-10 mg/kg) significantly prolonged tail bleeding time measured in conscious rats by two different techniques. While mianserin (a 5-HT2 receptor antagonist exhibiting alpha-adrenolytic activity) also prolonged bleeding time, methysergide, metergoline and cyproheptadine did not. All three compounds acted as 5-HT2 receptor antagonists with appreciable affinity for 5-HT1 receptors. On the other hand, bleeding time was prolonged by either prazosin (a selective alpha 1-adrenoceptor antagonist) or labetalol (an alpha 1- and beta-receptor antagonist). In contrast it was not affected by phentolamine or nicergoline (alpha 1-alpha 2-receptor antagonists) nor by propranolol (a beta-receptor antagonist). The effect of prazosin was significantly increased by combining it with either ketaserin or metergoline. Depletion of platelet serotonin by reserpine did not result in any modification of bleeding time, unless reserpine was combined with an inhibitor of 5-HT synthesis. Platelet activation by 5-HT was neither potentiated by norepinephrine nor prevented by prazosin or phentolamine whereas ketanserin and methysergide were equally effective inhibitors. These findings argue against a role of platelet and/or vascular 5-HT2 receptors in the antihemostatic effect of ketanserin in rats. This drug prolongs bleeding time by antagonising vascular adrenoceptors (prazosin-like effect) and/or by preventing a synergistic interaction between 5-HT and catecholamines at the vascular level.
mesh_terms: D000818:Animals; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D004347:Drug Interactions; D010134:Fenclonine / Q000494:pharmacology; D007650:Ketanserin; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000097:blood; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013565:Sympatholytics / Q000494:pharmacology; D013623:Tail / Q000098:blood supply
chemical_list: D010880:Piperidines; D012702:Serotonin Antagonists; D013565:Sympatholytics; D008711:Metergoline; D012701:Serotonin; D007650:Ketanserin; D010134:Fenclonine; D011224:Prazosin